drugset / Trial / NCT03350451
An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of lumasiran in participants with Primary Hyperoxaluria Type 1.
Timeline
- Start
- 2018-04-04
- Primary completion
- 2023-02-07
- Completion
- 2023-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lumasiran | Small interfering RNA (siRNA) | 3 mg/kg | Subcutaneous |